Henry Ford Health

Henry Ford Health Scholarly Commons
Pulmonary and Critical Care Medicine Articles

Pulmonary and Critical Care Medicine

3-31-2022

WASOG statement on the diagnosis and management of
sarcoidosis-associated pulmonary hypertension
Laurent Savale
Marloes Huitema
Oksana Shlobin
Vasilis Kouranos
Steven D. Nathan

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/pulmonary_articles

Authors
Laurent Savale, Marloes Huitema, Oksana Shlobin, Vasilis Kouranos, Steven D. Nathan, Hiliaro Nunes,
Rohit Gupta, Jan C. Grutters, Daniel A. Culver, Marco C. Post, Daniel R. Ouellette, Elyse E. Lower, Tamara
Al-Hakim, Athol U. Wells, Marc Humbert, and Robert P. Baughman

EUROPEAN RESPIRATORY REVIEW
REVIEW
L. SAVALE ET AL.

WASOG statement on the diagnosis and management
of sarcoidosis-associated pulmonary hypertension
Laurent Savale 1, Marloes Huitema2, Oksana Shlobin3, Vasilis Kouranos4,5, Steven D. Nathan3,
Hiliaro Nunes6, Rohit Gupta7, Jan C. Grutters8, Daniel A. Culver9, Marco C. Post2, Daniel Ouellette10,
Elyse E. Lower11, Tamara Al-Hakim12, Athol U Wells4,5, Marc Humbert 1 and Robert P. Baughman11
1
Université Paris–Saclay; INSERM UMR_S 999; Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs
Respiratoires, Hôpital Bicêtre, Le Kremlin Bicêtre, France. 2Dept of Cardiology, St. Antonius Hospital, Nieuwegein and University
Medical Center Utrecht, Utrecht, The Netherlands. 3Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls
Church, VA, USA. 4Interstitial Lung Disease/Sarcoidosis Unit, Royal Brompton Hospital, London, UK. 5National Heart and Lung
Institute, Imperial College, London, UK. 6INSERM UMR 1272, Université Sorbonne Paris Nord; Service de Pneumologie, Centre de
Référence des Maladies Pulmonaires Rares, APHP, Hôpital Avicenne, Bobigny, France. 7Dept of Thoracic Medicine and Surgery, Lewis
Katz School of Medicine at Temple University, Philadelphia, PA USA. 8Dept of Pulmonology, ILD Center of Excellence, St. Antonius
Hospital, Nieuwegein and University Medical Center Utrecht, Utrecht, The Netherlands. 9Cleveland Clinic, Cleveland, OH, USA. 10Henry
Ford Hospital, Detroit, MI, USA. 11Dept of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA. 12Foundation for
Sarcoidosis Research, Chicago, IL USA.

Corresponding author: Robert P. Baughman (baughmrp@ucmail.uc.edu)

Shareable abstract (@ERSpublications)
Sarcoidosis-associated pulmonary hypertension is a significant cause of morbidity and mortality.
A guide to screening, diagnosis and treatment has been developed by a team of experts.
https://bit.ly/3FzOcgb
Cite this article as: Savale L, Huitema M, Shlobin O, et al. WASOG statement on the diagnosis and
management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022; 31: 210165
[DOI: 10.1183/16000617.0165-2021].

Copyright ©The authors 2022
This version is distributed under
the terms of the Creative
Commons Attribution
Non-Commercial Licence 4.0.
For commercial reproduction
rights and permissions contact
permissions@ersnet.org
Received: 9 July 2021
Accepted: 13 Nov 2021

Abstract
Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced
sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and
treatment of SAPH. This includes the results of two large SAPH-specific registries. A task force was
established by the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) to
summarise the current level of knowledge in the area and provide guidance for the management of
patients. A group of sarcoidosis and pulmonary hypertension experts participated in this task force. The
committee developed a consensus regarding initial screening including who should undergo more specific
testing with echocardiogram. Based on the results, the committee agreed upon who should undergo rightheart catheterisation and how to interpret the results. The committee felt there was no specific phenotype
of a SAPH patient in whom pulmonary hypertension-specific therapy could be definitively recommended.
They recommended that treatment decisions be made jointly with a sarcoidosis and pulmonary
hypertension expert. The committee recognised that there were significant defects in the current knowledge
regarding SAPH, but felt the statement would be useful in directing future studies.
Introduction
Pulmonary hypertension (PH) is haemodynamically defined by right-heart catheterisation (RHC) by a
mean pulmonary artery pressure (mPAP) above 20 mmHg. Post-capillary PH is characterised by a
pulmonary artery wedge pressure (PAWP) above 15 mmHg while pre-capillary PH is defined by PAWP
⩽15 mmHg and pulmonary vascular resistance (PVR) >3 Wood’s units (WU). Right ventricle (RV)
remodelling and dysfunction induced by increased afterload results in exercise limitation and death. The
purpose of the recently updated PH 6th World Symposium clinical classification was to categorise clinical
conditions associated with PH based on similar pathophysiological mechanisms, clinical presentation,
haemodynamic characteristics and therapeutic management. Sarcoidosis-associated pulmonary hypertension
(SAPH) can be caused by different and sometimes overlapping mechanisms and it has remained in Group
5 of the clinical classification of PH. SAPH is a significant cause of morbidity and mortality in patients
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with advanced sarcoidosis [1, 2]. The reported incidence of SAPH has been around 5% in studies from
across the world. Higher incidences were reported in patients who had persistent dyspnoea or who were
being evaluated for lung transplantation (figure 1) [3–16]. Over the past few years, there has been
increasing recognition of the prevalence of this major complication of sarcoidosis, as well as studies
regarding screening/early detection, diagnosis and treatment.
Based on the increasing evidence and the need for better awareness of SAPH, a task force was established
by the World Association of Sarcoidosis and Other Granulomatous diseases (WASOG) and the Foundation
for Sarcoidosis Research (FSR). This global task force was chaired by three international experts: two of
sarcoidosis (RP Baughman, AU Wells) and one of PH (M Humbert). The committee met physically and
virtually over 3 years (2019–2021). The committee acknowledges that the present recommendations were
for the most part based on limited information available for SAPH. Many organisations such as the
European Respiratory Society use the GRADE method and PICO questions ( patient, intervention,
comparison, outcomes) [17] for clinical practice guidelines. We decided not to use this approach because
there were too few well-designed large multicentre SAPH registries and randomised clinical trials. The
committee therefore focused on specific areas regarding screening, diagnosis and treatment and made
specific comments (table 1). The comments were based on a literature review and a series of polls of the
committee members to provide answers where there was consensus among the committee members.
Consensus was defined as >70% of voting members agreeing on an individual statement. This Statement is
narrative and pragmatic rather than systematic and is further complemented by a description of usual
clinical practice and the experience of the panel members [18]. This Statement summarises the current state
of knowledge and it does not make formal recommendations for clinical practice.
SAPH clinical outcomes
Is SAPH associated with increased morbidity?
The presence of PH in sarcoidosis is associated with greater supplemental oxygen requirements [10, 12,
15, 19, 20] as exemplified by an analysis of 363 patients with sarcoidosis listed for lung transplantation, in
which subjects with SAPH required more supplemental oxygen (2.7±1.8 versus 1.6±1.4 L·min−1)
compared with those without PH [15]. In the ReSAPH registry analysis of 176 patients, most desaturated
during the 6-min walk test (6MWT), with a median degree of desaturation of 5% [20]. Similarly, in the
French Registry cohort of 126 patients with moderate-to-severe SAPH followed over a 10-year period,
54% were on long-term oxygen [21]. Presence of SAPH also increases the burden on functional capacity
[10, 22–24], employment status and need for caregiver assistance [19]. In the French Registry, 83% of the
patients with SAPH reported World Health Organization (WHO) functional class (FC) III–IV symptoms
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FIGURE 1 The reported incidence of SAPH from various centres across the world. The city or country of origin
of the study is indicated. A higher incidence of SAPH was found for patients being evaluated for persistent
dyspnoea or lung transplantation [3–16]. SAPH: sarcoidosis-associated pulmonary hypertension; UNOS: United
Network Organ Sharing.
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TABLE 1 Summary of Task Force comments.
1. Presence of SAPH is associated with significant symptomatology and morbidity, as evidenced by increased
WHO FC, decreased 6MWD or desaturation and increased oxygen use.
2. Pulmonary hypertension is an independent predictor of mortality in patients with sarcoidosis.
3. Since the cause of SAPH is multifactorial, the committee commented that the current recommendation to
keep SAPH in Group 5 was reasonable. The committee considered that patients with left ventricular disease
either due to sarcoidosis or other conditions should be treated as WHO Group 2. The committee felt it was
important to identify a dominant cause for SAPH on an individual basis, as it is likely to have treatment
implications.
4. The suggestions of who should undergo transthoracic echocardiogram are summarised in figure 3.
5. The committee’s suggestions regarding who should undergo RHC are summarised in figure 5.
6. The committee suggested that the right-heart catheterisation results should be interpreted by a
multidisciplinary team with at least a sarcoidosis and PH expert and decisions should be made as
summarised in figure 6.
7. Evaluate for pulmonary artery stenosis or mediastinal compression by chest imaging.
8. In SAPH, treatment decision and follow-up should be made by a multidisciplinary team with a sarcoidosis
and a PH expert. Off-label use of PAH medical therapy may be considered for symptomatic patients on a
case-by-case basis (figure 7).
9. Patients who have failed to respond to treatment for PH should be referred for lung transplant evaluation, if
they are deemed otherwise to be appropriate candidates.
SAPH: sarcoidosis-associated pulmonary hypertension; WHO FC: World Health Organization Functional Class;
6MWD: 6-min walk distance; RHC: right-heart catheterisation; PH: pulmonary hypertension; PAH: pulmonary
arterial hypertension.

[21]. In the Duke cohort of 95 patients followed for 11 years, almost all patients (99%) were symptomatic
with activity (WHO FC II–IV symptoms) and 77% of the cohort reported WHO FC III/IV symptoms [22].
In a small British cohort of 24 patients, 48% had WHO FC III symptoms, while 42% had WHO FC IV
symptoms [23]. Moreover, objective assessment of functional capacity supports subjectively reported
decreased exercise tolerance in patients with SAPH. The 6-min walk distance (6MWD) was consistently
found to be reduced in several studies, with mean values ranging between 305 and 320 metres [20, 21, 24].
The French Registry analysis which captured dyspnoea assessed by the Borg scale found it to be elevated
at 4.0±2.3 [21] during the performance of the 6MWT.
Summary
Presence of SAPH is associated with significant symptomatology and morbidity, as evidenced by increased
WHO FC, decreased 6MWD or desaturation and increased oxygen use.
Is SAPH an independent predictor of mortality?
Several studies have assessed the presence of RV dysfunction in patients with SAPH. In the Duke cohort,
the median N-terminal pro-brain natriuretic peptide (NT-proBNP) level at the time of initial evaluation was
910 pg·mL−1 (Q1–Q3: 225–2807). On transthoracic echocardiogram, the majority (59%) of patients had
either moderate or severe RV enlargement and 55% had moderate or severe RV dysfunction [22].
Interestingly, in this cohort, neither baseline echocardiographic nor haemodynamic characterisation of RV
function were associated with outcomes, but follow-up NT-proBNP levels were higher in those who died
or were hospitalised (1258.0 versus 262.0 pg·mL−1, p=0.007).
The mortality implications of any PH, both pre- and post-capillary, in the context of sarcoidosis are also
profound, with a 10-fold increase in mortality and an estimated 5-year survival of only 59% [1, 14, 25].
Figure 2 shows the 1-, 3-, and 5-year survival reported from several centres across the world [7, 13, 21, 23,
24]. In the Duke cohort, the median time from diagnosis of SAPH to either death or hospitalisation was
6 months (Q1–Q3: 3.0–12.0 months) [22]. Patients with SAPH are more likely to be listed for lung
transplant and also have a greater likelihood of succumbing while on the waiting list [15, 26]. In the
British cohort, the rate of mortality or transplantation was 41.2% with the median survival without
transplantation being 5.3 years. In that study, more patients who died or underwent transplantation during
follow-up had baseline RV dysfunction (80%) [23]. The ReSAPH registry analysis of 159 patients with
pre-capillary SAPH demonstrated the 1-, 3- and 5-year transplant-free survival to be 83.7%, 70.6% and
58.5%, respectively. Severe gas transfer impairment (diffusing lung capacity for carbon monoxide (DLCO)
<35% predicted) and 6MWD <300 m were strong predictors of decreased survival ( p=0.0151 and p
<0.0001, respectively) [24]. These results were similar to the French Registry, which demonstrated 3- and
5-year survival rates of 74% and 55%, respectively [21].
https://doi.org/10.1183/16000617.0165-2021
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FIGURE 2 The 1-, 3- and 5-year survival from sarcoidosis-associated pulmonary hypertension [7, 13, 21, 23, 24].
#
: For three of the studies [7, 13, 23], the survival was estimated based on the Kaplan–Meier survival curves
presented in the papers.

In patients with SAPH from the French Registry, univariate analysis showed that WHO FC IV, 6MWD
and reduced forced vital capacity (FVC) or DLCO were associated with a poor survival [21]. In multivariate
analysis, only 6MWD remained independently associated with mortality [21]. It is still not clear if patients
with SAPH are succumbing because of PH or in the presence of PH. In one study, which demonstrated
that SAPH was associated with mortality, the only haemodynamic factor that remained predictive of
mortality after multivariable analysis was the right arterial pressure [26]. In another study of a small cohort
of 24 patients, presence of right ventricular dysfunction on echocardiography was the most powerful
predictor of death or transplantation (OR 83.1, 95% CI 2.2–31.02, p=0.017) [23]. This evidence of
right-sided heart failure implies that patients with SAPH are indeed dying from their PH, rather than the
PH being an epiphenomenon.
In two multi-regression analyses PH has been found to be an independent risk factor for mortality [1, 2].
In evaluating patients awaiting lung transplant the final prediction model for mortality included mPAP
[19]. In an analysis of fibrotic sarcoidosis patients, presence of PH by echocardiography had a hazard ratio
for mortality of 3.42. In the study by KIRKIL et al. [1], haemodynamically confirmed pre-capillary SAPH
had a hazard ratio of 8.96 and, along with fibrosis >20% by high-resolution computed tomography
(HRCT) and age, remained an independent predictor of mortality by Cox modelling.
Summary
PH is an independent predictor of mortality in patients with sarcoidosis.
Classification/cause of SAPH
Should SAPH be divided into various subclasses
SAPH can be caused by a variety of mechanisms (table 2). Due to the predilection of granulomas for the
lymphatics, which are found in the bronchovascular bundles and the interlobular septae, pulmonary
vascular granulomatous involvement typically occurs on both the arterial and venous sides of the
circulation. In one study of organ explants from patients with sarcoidosis undergoing lung transplantation,
features of venous involvement were identified in addition to arterial disease [25]. An increased incidence
of pulmonary emboli is frequently encountered in sarcoidosis patients [27–29], and chronic
thromboembolism can potentially lead to Group 4 PH [30]. Interstitial changes are also highly associated
with the development of PH [20, 21]. Although more than half of patients with SAPH have clinical
fibrotic lung disease, most studies confirm that up to 20% of patients with SAPH have no radiographic
evidence of parenchymal lung disease [12, 20, 31]. Alveolar hypoxia, most frequently in the setting of
parenchymal involvement, may also contribute to the development of PH. Hilar adenopathy compressing
the pulmonary arteries and veins can also lead to PH. However, compression usually has to be of multiple
vessels to lead to significant PH. In a study of 156 patients with SAPH, significant compressive hilar
adenopathy leading to PH was identified in only two patients [21]. Fibrosing mediastinitis due to
sarcoidosis can also contribute to PH [32–34]. In the French Registry, 3 of 156 patients with SAPH had
fibrosing mediastinitis as the identified cause [21]. In a prospective study of 72 patients with SAPH from a
https://doi.org/10.1183/16000617.0165-2021
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TABLE 2 Causes of pulmonary hypertension in sarcoidosis patients
Condition

Potential treatments

Vascular disease
Vasculitis
Granulomatous vascular involvement
Veno-occlusive disease
Pulmonary embolism (CTEPH)

Interstitial lung disease
Parenchymal lung disease due to granulomas
Parenchymal lung disease due to fibrosis
Hilar and mediastinal distortion
Pulmonary artery/vein extrinsic compression
Fibrosing mediastinitis
Extrapulmonary disease
Left ventricular systolic dysfunction
Left ventricular diastolic dysfunction
Sleep apnoea
Liver disease

Glucocorticoids and other anti-inflammatory treatments
Pulmonary vasodilators
Glucocorticoids and other anti-inflammatory treatments
Pulmonary vasodilators
Glucocorticoids and other anti-inflammatory treatments
Careful use of pulmonary vasodilators
Anticoagulation
Balloon pulmonary angioplasty
Pulmonary endarterectomy
Pulmonary vasodilators
Glucocorticoids and other anti-inflammatory treatments
Anti-fibrotic agents
Glucocorticoids and other anti-inflammatory treatments
Dilation and/or stenting of compressed vessels
Dilation and/or stenting of compressed vessels
Glucocorticoids and other anti-inflammatory treatments
Diuretics, afterload reduction
Diuretics
CPAP, oxygen and other measures
Glucocorticoids and other anti-inflammatory treatments

CTEPH: chronic thromboembolic pulmonary hypertension; CPAP: continuous positive airway pressure.

single institution, eight patients were found to have vascular compression/distortion. In all eight patients,
stenting was successful in reducing pulmonary artery pressure [35].
Left ventricular disease can lead to development of post-capillary PH. In one study, approximately 20% of
patients with SAPH demonstrated elevated PAWP, consistent with left ventricular failure [14]. Sarcoidosis
patients may have comorbid coronary artery disease. This can be a cause of significant morbidity in
sarcoidosis [36]. Evaluation of patients with elevated pulmonary artery pressure should exclude left
ventricular disease as the basis of either ischaemic or nonischaemic heart disease. Granulomatous
inflammation can also cause an infiltrative cardiomyopathy often leading to left heart failure [37].
However, in some cases, the left ventricular ejection fraction may be normal or only mildly impaired but
still have a less compliant left ventricle [38, 39].
Sleep-related breathing disorders can contribute to PH [40, 41], and patients with sarcoidosis have an
increased incidence of obstructive sleep apnoea syndrome (OSAS) [42–44]. Of note, chronic use of
corticosteroids increases the risk for OSAS in sarcoidosis patients, regardless of gender of patient [44]. If
OSAS is diagnosed, treatment with continuous positive airway pressure (CPAP) should be initiated.
Although the liver is one of the most commonly affected organs in sarcoidosis [45, 46], severe liver
disease is relatively uncommon [47, 48] and portopulmonary hypertension is rarely seen.
Summary
Since the cause of SAPH is multifactorial, the committee commented that the current recommendation to
keep SAPH in Group 5 was reasonable. The committee considered that patients with left ventricular
disease either due to sarcoidosis or other conditions should be treated as WHO Group 2. The committee
felt it was important to identify a dominant cause for SAPH on an individual basis, as it is likely to have
treatment implications.
Screening and diagnosis of SAPH
Who should get a transthoracic echocardiogram?
Screening is defined as the systematic use of a test, or tests, in at-risk individuals to identify disease before
symptom onset. Previous studies have shown that screening allows earlier management and better clinical
outcome in patients with systemic sclerosis-associated pulmonary arterial hypertension (PAH) [49]. While
https://doi.org/10.1183/16000617.0165-2021
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the consequences of SAPH screening remains unknown, the task force felt that it is desirable to improve
awareness of this severe complication of sarcoidosis in an attempt to diagnose it earlier when functional
impairment and haemodynamics are less severely compromised. Therefore, screening (in asymptomatic
patients) and early diagnosis (when symptoms and functional impairment are present) have the potential to
identify SAPH at an early stage. It has been previously recommended using GRADE methodology that a
transthoracic echocardiogram should be performed in those patients with sarcoidosis in whom PH is
suspected (conditional recommendation) [50].
The task force evaluated what factors would lead to the decision to perform a transthoracic echocardiogram
in patients with sarcoidosis and identified several features which were likely to be associated with SAPH
(figure 3). The task force felt the presence of one or more of these features should lead to
echocardiography. RHC should be performed when echocardiography gives a high or intermediate
probability of PH (according to the ESC/ERS PH guidelines) (figure 4) [51] and for all patients being
considered for lung transplant. For those patients, the RHC should be followed by left catheterisation and
coronarography because of the potential implication of the results for the patient’s management and on
future lung transplantation in eligible cases (timing of transplantation, lung or heart-lung transplantation,
need of extracorporeal circulation). Over 70% of sarcoidosis patients undergoing lung transplant will have
SAPH and presence of SAPH increases the indication for transplant [16, 19]. However, SAPH was not
associated with higher mortality after transplant [52]. While a recent study did not find that SAPH
was associated with increased mortality for patients on the lung transplant list [53], patients with SAPH
still had significant morbidity.
Other features, ranging from chest imaging to serum biomarkers, have been associated with the presence of
SAPH and therefore could be considered as part of the screening process. In three large studies,
approximately half of sarcoidosis patients with persistent dyspnoea despite anti-inflammatory therapy were
noted to have SAPH [11, 12, 14]. These studies did not identify which specific complaint or level of
dyspnoea led to further evaluation. However, all three studies found that the rate of SAPH was up to ten

Clinical signs, circulating biomarkers,
imaging and/or ECG features suggestive of
PH (≥1 criteria)

All sarcoidosis patients candidates
for
lung transplantation

• Persistent dyspnoea despite aggressive anti-inflammatory therapy
• Clinical signs of right ventricular failure
• 6MWD of <300 m and/or desaturation >5%
• >20% decrease in 6MWD without modification of PFTs
• High level of BNP or NT-proBNP#
•
•
•
•

Pulmonary fibrosis >20% of lung parenchyma
Increased pulmonary artery to aorta ratio¶
Suspicion of PH and/or RV dysfunction on cardiac MRI
Signs of PH on contrast CT scan

• Worsening of NYHA-FC without modification of FVC
• >15% decrease in DLCO without modification of FVC, especially if other signs of PH are present

Transthoracic doppler echocardiography to estimate PH probability

FIGURE 3 Algorithm for who should undergo transthoracic echocardiogram to evaluate for SAPH. 6MWD: 6-min walk distance; BNP: B-type
natriuretic peptide; BSA: body surface area; CT: computed tomography; DLCO: diffusing capacity of the lung for carbon monoxide; ECG:
electrocardiogram; FVC: forced vital capacity; MRI: magnetic resonance imaging; NT-proBNP: N-terminal (NT)-pro hormone BNP; NYHA-FC: New York
Heart Association functional class; PFT: pulmonary function test; PH: pulmonary hypertension; RV: right ventricle; SAPH: sarcoidosis-associated
pulmonary hypertension. #: Transthoracic echocardiogram recommended to assess for SAPH and left ventricular dysfunction. ¶: May be more
accurate if corrected for BSA.
https://doi.org/10.1183/16000617.0165-2021
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Peak tricuspid regurgitant
velocity, m·s–1

Presence of other echo PH signs
(see below)

Low

≤2.8 or not measurable

No

Intermediate

≤2.8 or not measurable

Yes

Echo suggestive of PH

Intermediate
High
High

2.9–3.4
2.9–3.4
>3.4

No
Yes
Not required

Pulmonary artery

Inferior vena cava and right atrium

Presence of other echo PH signs:
The ventricles
Right ventricle/left ventricle basal
diameter ratio >1.0

Right ventricular outflow Doppler
acceleration time <105 msec and/or
mid systolic notching

Flattening of the interventricular
Early diastolic pulmonary
septum (left ventricular eccentricity regurgitation velocity >2.2 m·s–1
index >1.1 in systole and/or diastole)

Inferior cava diameter >21 mm with
decreased inspiratory collapse
(<50% with a sniff or <20% with
quiet inspiration)
Right atrial area (end-systole)
>18 cm2

PA diameter >25 mm

FIGURE 4 Probability of pulmonary hypertension from echocardiography findings of direct estimate of right
ventricular systolic pressure and indirect evidence of right ventricular strain. Reproduced from GALIE et al. [51].
PA: pulmonary artery; PH: pulmonary hypertension.

times higher than the general sarcoidosis population. Patients with SAPH generally have a median 6MWD
of <350 m [9, 20, 21, 54]. Most patients also desaturate >5% during the test [9]. It has also been noted
that some patients with SAPH have elevated serum B-type natriuretic peptide (BNP) and NT-proBNP
levels [8, 22, 55]. Chest imaging has also been shown to be abnormal in SAPH patients. Patients with
SAPH are more likely to have pulmonary fibrosis than a comparable symptomatic group [11, 12]. This has
led to the recommendation that all sarcoidosis patients with fibrosis be screened for SAPH [56]. However,
there was the concern among the committee about the variable interpretation of presence of pulmonary
fibrosis on chest radiograph [57]. The presence of greater than 20% fibrosis on HRCT has proved a more
reproducible assessment of fibrosis with good agreement between radiologists and clinicians [58, 59]. The
presence of >20% fibrosis on HRCT has been found to be associated with increased mortality in
pulmonary sarcoidosis [1, 2, 58]. The presence of an increased pulmonary artery diameter, corrected for by
either aorta diameter or body surface area [2, 60, 61], is associated with SAPH. The group also reached
consensus regarding an enlarged right ventricle on a contrast computed tomography (CT) scan as an
indicator for the patient to have a transthoracic echocardiogram. Cardiac MRI findings of RV dysfunction
or PH have been reported in SAPH [62, 63]. Cardiac MRI is useful in identifying cardiac sarcoidosis and
as a result any potential treatment implications. Several studies in patients with SAPH have shown that
patients with SAPH have a degree of pulmonary restriction (FVC <60% pred) and at least moderate gas
transfer impairment (DLCO <50% pred) [11, 12, 24]. Patients with sarcoidosis such lung function
parameters would be considered for SAPH screening. Using the paradigm of systemic sclerosis-associated
PH, a KCO (transfer coefficient of the lung for carbon monoxide) <60% pred or an FVC/ DLCO ratio >1.6
may be parameters predicting SAPH [49].
There was consensus that the presence of one or more of these factors should lead to echocardiography to
determine the probability of PH. In addition, other features were identified by the group and consensus for
screening echocardiography was achieved if there is a worsening of New York Heart Association (NYHA)
functional class, a decrease >20% in the 6MWD, or a decrease >15% of the DLCO when there was no
significant change in lung volumes.
Summary
The suggestions of who should undergo transthoracic echocardiogram are summarised in figure 3.
Who should get right-heart catheterisation?
RHC is the gold standard for diagnosing PH. It has been recognised for several years that
echocardiography may over or underestimate pulmonary arterial pressure (PAP), especially in those with
https://doi.org/10.1183/16000617.0165-2021
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Echocardiogram

High probability

Intermediate
probability

Low probability

Inconclusive

Proceed to RHC

FVC<50%

Decision on RHC
made on a caseby-case basis

Decision on RHC made
on a case-by-case basis

No
Proceed to RHC

RHC, if being considered for
transplantation

Yes

Decision on RHC made
on a case-by-case basis

FIGURE 5 Algorithm for who should undergo RHC based on echocardiography. FVC: forced vital capacity; RHC:
right-heart catheterisation.

interstitial lung disease [64, 65]. In sarcoidosis, RHC can be particularly helpful in separating pre- and
post-capillary PH [14]. A transthoracic echocardiogram can estimate the probability of PH and raise
suspicion, but it cannot define SAPH. The echocardiogram can provide information regarding RV function
and evaluate left ventricular function may suggest post-capillary PH. However, a RHC remains the
definitive test to distinguish between pre- and post-capillary PH [14]. Therefore, the committee felt the
results of echocardiography should be used to determine who should undergo RHC.
The estimated RV systolic pressure based on tricuspid regurgitation velocity (TRV) is the most validated
echocardiographic parameter to screen for PH. However, the echo may not be a well visualised tricuspid
regurgitation (TR) jet seen on transthoracic echocardiogram. Also, other signs suggestive of PH may be
seen on transthoracic echocardiogram when analysing the ventricles, the pulmonary arteries, the inferior
vena cava and right atrium. The ESC/ERS PH guidelines [51] have proposed a simple algorithm which
allows one to incorporate both the TRV and other indirect measures (figure 4) leading to a scoring of
patients as having high, intermediate or low probability for PH. For SAPH, for those with low probability,
the decision to proceed with a right catheterisation should be made on a case-by-case basis. For those in
whom the results were inconclusive, the patient should be considered on a case-by-case basis (figure 5)
with a joint decision between a PH and a sarcoidosis expert. Factors which may influence the decision to
perform a RHC include echocardiographic evidence for RV dysfunction (figure 4), pulmonary function
tests, 6MWT, BNP or NT-proBNP and imaging results. For members of the committee, there was not
agreement regarding systematically performing a RHC in those with an intermediate probability of PH
associated with severe interstitial lung disease. The presence of right ventricular dysfunction on
echocardiogram adds further support to the decision to proceed with RHC, but there was insufficient
evidence in sarcoidosis to make this a formal recommendation. Some felt this was not needed unless in the
context of a lung transplant evaluation. Others felt that the decision for RHC should be made on a
case-by-case basis. This ambivalence is predicated by the current literature that suggests this group may
not be responsive to PAH therapies.
Summary
The committee’s suggestions regarding who should undergo RHC are summarised in figure 5.
How should one interpret RHC in SAPH?
The committee felt that the RHC should be performed in a PH expert centre and its results (and
consequences) should be interpreted by a multidisciplinary team with expertise in PH, sarcoidosis, imaging
https://doi.org/10.1183/16000617.0165-2021
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and transplantation, if available and appropriate. In some cases, the sarcoidosis and PH expert may be the
same person. A cardiologist’s input is needed for those with post-capillary PH to distinguish
sarcoidosis-related causes from left-sided heart failure. Review of the RHC tracings may be useful in order
to precisely define the pre- or post-capillary mechanisms of PH.
Figure 6 summarises the suggestions of the committee on assessing the RHC. For patients with an elevated
mPAP (>20 mm Hg), the results of the PAWP measurement will determine whether this is pre- or
post-capillary PH (WHO Group 2). As noted in the figure, a PAWP >15 mm Hg confirms a post-capillary
PH. If there is any uncertainty about the validity of the PAWP measurement, then direct measurement of the
left ventricular end-diastolic pressure measurement should be considered. The distinction is important for both
treatment decisions as well as prognosis [14]. The committee recognised that patients might have combined
pre- and post-capillary PH which can be either due to pre-capillary vascular changes due to left heart disease
or due to sarcoidosis-related factors. Therefore, careful follow-up evaluation after the initial treatment decision
should be undertaken for these patients in particular to ensure that the chosen treatment course is accompanied
by a salutary and not a deleterious response. Pre-capillary PH due to pulmonary vascular disease is robustly
defined when the PVR is ⩾3 WU but remains likely when the PVR is between 2 and 3.
For patients with a mean PAP of <20 mm Hg, the clinician should look elsewhere for the cause of
symptoms and offer regular follow-up.
In patients with a PAWP 13–15 mmHg, left-sided cardiac involvement can still be contributory to PH.
However, a RHC occasionally with the need for provocative manoeuvres, such as fluid challenge or
exercise, remains the definitive test to distinguish between pre and post-capillary PH.
The cardiac MRI may provide additional information in these cases. It may indicate cardiac involvement as
the cause of increased pressures, especially for those WHO Group 2 patients. These patients should still be
considered for a multidisciplinary discussion [37]. In addition, the presence of right ventricular
abnormalities were prognostic factors in a population of sarcoidosis patients with suspected cardiac
sarcoidosis [66]. No study has been conducted to the correlation between right ventricular sarcoidosis and
the presence of PH.
Summary
The committee indicated that the RHC results should be interpreted by a multidisciplinary team with at
least a sarcoidosis and PH expert and decisions should be made as summarised in figure 6.

Pre-capillary PH
mPAP >20 mmHg
PAWP ≤15 mmHg
PVR ≥3 WU

Yes
PH related to parenchymal lung disease

Concordant parenchymal
disease?
Consider other factors contributing to PH

Combined pre- and postcapillary PH¶
mPAP >20 mmHg
PAWP >15 mmHg
PVR ≥3 WU
Consider left heart disease
and/or cardiac sarcoidosis#
Isolated post-capillary PH
WHO group 2
mPAP >20 mmHg
PAWP >15 mmHg
PVR <3 WU

Sarcoidosis related:
Granulomatous pulmonary vasculopathy
Extrinsic compression of pulmonary vasculature
Portal hypertension
No
Related comorbidities:
Uncorrected or nocturnal hypoxaemia
Obstructive sleep apnoea
Chronic thromboembolic PH

FIGURE 6 Interpretation of right-heart catheterisation and subsequent treatment recommendations are made in the figure. mPAP: mean
pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; WHO:
World Health Organization; WU: Wood’s unit. #: Cardiac sarcoidosis may be evident in pre-capillary PH without changing haemodynamics. ¶: Careful
evaluation should be performed by a cardiologist/PH specialist to distinguish PH due to left heart disease with subsequent pre-capillary vascular
changes and sarcoidosis-associated PH.
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TABLE 3 Treatment of pre-capillary SAPH

Prostenoids
Epoprostenol
Iloprost

Highest level of evidence study in
patients with SAPH

Total number of patients with
SAPH treated

Results in sarcoidosis

Retrospective OL positive [78, 79]
Prospective, OL [72]

12
15 of 22 enrolled completed
16 weeks’ therapy

Haemodynamics improved [78, 79]
In sarcoidosis, haemodynamics and
QoL improved [72]

DBPC [71]

23

Prospective OL [73]

21

Retrospective OL [82]

6

Haemodynamics improved, no change
in 6MWD [71]
Nonsignificant improved QoL, no
change 6MWD [73]
WHO FC improved in 4/6 treated
patients [82]

Retrospective OL [16]

12

Prospective OL [74]

12

DBPC [70]

16

Retrospective OL positive [8, 21, 77]

29

Endothelin receptor
antagonists
Bosentan
Ambrisentan
Macitentan
Phosphodiesterase 5 inhibitors
Sildenafil
Tadalafil
Others
Riociguat
Combination therapy

Haemodynamics improved, 6MWD
no changes
No significant changes in 6MWD
and QoL
TCW and 6MWD significantly better
compared with placebo
Haemodynamics and 6MWD improved
in some

SAPH: sarcoidosis-associated pulmonary hypertension; OL: open-label; QoL: quality of life; DBPC: double-blind, placebo-controlled; 6MWD: 6-min
walk distance; WHO FC: World Health Organization functional class; TCW: time to clinical worsening.

Treatment
Should pulmonary vasculature be visualised to rule in/out narrowing
SAPH may be caused by direct compression of the pulmonary artery by either mediastinal adenopathy or
fibrosis. For patients with adenopathy compressing the pulmonary arteries, anti-inflammatory therapy may
lead to reduction of the size of the nodes and relief of the compression. BOUCLY et al. [21] identified this
situation in five of their 126 (4%) patients with severe SAPH. The authors performed positron emission
tomography (PET) scanning to detect this situation. Distortion of the vasculature due to mediastinal
fibrosis can also lead to SAPH. In some cases, stenting of the vasculature may reduce PAP [35, 67]. In a
prospective study, all patients with SAPH underwent computer tomographic pulmonary angiography. Eight
of 72 (11%) were found to have significant pulmonary artery stenosis and underwent successful stenting to
relieve pressure [35]. A recent meta-analysis of the literature found that pulmonary artery angioplasty with
or without stenting was successful in improving 6MWD [68].
Summary
Evaluate for pulmonary artery stenosis and mediastinal compression chest imaging.
Should pre-capillary SAPH be treated?
The committee focused on treatment of pre-capillary PH. The World Symposium on Pulmonary
Hypertension concluded in 2019 that there was insufficient information to make routine recommendations
for therapy in SAPH [69]. The results of treatment of SAPH for individual PAH drugs are summarised in
table 3 [70–82], with results from the studies with the highest level of evidence for each treatment
presented. To date, there have been only two double-blind, placebo controlled (DBPC) trials for SAPH
[70, 71]. Three studies reported the results of prospective open label trials [72–74]. The remaining studies
were retrospective case series. Initial or sequential combination therapy has been shown to be effective in
treating PAH [75, 76]. Three series have reported the outcome of treatment with various treatment
regimens in SAPH [8, 21, 77]. In those studies, measuring haemodynamics before and after therapy, the
majority of patients showed improvement [8, 16, 21, 71, 72, 77–79]. There was only one study evaluating
haemodynamics for placebo-treated patients demonstrating no significant change in pressures after
16 weeks [71]. Other end-points, including 6MWD and quality of life measures, had more mixed results.
As summarised in table 3, not all studies found a positive response to treatment in SAPH. To date, only
https://doi.org/10.1183/16000617.0165-2021
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one study has evaluated time to clinical worsening (TCW) with therapy [70]. That study has been
published online and did find a significant improvement in TCW for riociguat compared with placebo.
Because of the limited number of randomised trials, the committee did not feel any specific
recommendation could be made regarding one or other agent to treat pre-capillary PH, The committee felt
that off-label use of PAH drugs may be considered on a case-by-case basis [21, 22]. While not specifically
studied in any of the trials, the committee felt that specific PAH therapies should be considered after
taking into account the mechanisms involved in the development of PH, the severity of PH and the
severity of the underlying parenchymal lung disease. Table 2 points out the various factors which can lead
to SAPH. Therapy for pre-capillary hypertension is directed to vascular disease. Care must be taken when
using these treatments in patients with veno-occlusive disease. For those with moderate-to-severe
parenchymal lung disease (FVC <50% pred), treatment of SAPH may not be as effective. However, if
there is evidence for RV dysfunction, treatment of SAPH may still be indicated. For patients with milder
SAPH, other factors may be the major cause of patient’s symptoms. A recently published study did
demonstrate that treatment of mild PH in idiopathic interstitial lung disease was associated with a positive
response [80]. However, that study did not include sarcoidosis patients. Worsening of ventilation/perfusion
mismatch may occur with pulmonary vasodilator therapy, but in one 16 week study the frequency was
similar to that seen with placebo-treated patients [71]. Another potential limitation is uncovering
pulmonary veno-occlusive disease (PVOD) [79]. Treatment decision and follow-up should be made by a
multidisciplinary team with a sarcoidosis and a PH expert.
Summary
In SAPH, treatment decision and follow-up should be made by a multidisciplinary team with a sarcoidosis
and a PH expert. Off-label use of PAH therapy may be considered for symptomatic patients on a
case-by-case basis (figure 7). As noted above, nearly three-quarters of sarcoidosis patients listed for lung
transplant have SAPH [16, 19]. It has been observed that post-transplant survival in patients with pulmonary
sarcoidosis was similar to that in patients with other indications for lung transplantation [52, 81].
Summary
Patients who have failed to respond to treatment for PH should be referred for lung transplant evaluation, if
they are deemed otherwise to be appropriate candidates.

Oxygen ± diuretics

Treat underlying inflammation of sarcoidosis

Evaluate for pulmonary artery stenosis and
mediastinal compression by chest imaging

Discuss treatment of pre-capillary pulmonary hypertension in all patients
Consider all these treatments on a case-by-case basis
Intravenous/inhaled prostacyclins
Endothelin receptor antagonists
PDE-5 inhibitors
Riociguat

Response:
continue therapy

No response

FVC >50% predicted
Combination therapy

FVC <50%

No response

Consider for lung transplant

FIGURE 7 Proposed algorithm for treating pre-capillary sarcoidosis-associated pulmonary hypertension. FVC:
forced vital capacity; PDE-5: phosphodiesterase 5.
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Future research and next steps
Screening
The development of noninvasive screening tools, including serum biomarkers and MRI, need to be further
evaluated in SAPH. In addition, the indications for when to repeat screening for SAPH need to be better
defined.
Treatment trials
The first priority is the need to develop therapy for SAPH based on well-designed placebo controlled trials.
The data summarised in this statement provide ample support for the likelihood that highly efficacious
therapies will emerge and the existence of a large multinational SAPH registry indicates that the
sarcoidosis community is now geared for definitive studies. The recent treprostinil data in nonsarcoid
interstitial lung disease (ILD)-PH [80], suggesting major efficacy in the short-term, is an additional spur:
based on past data, there has been more basis for optimism in SAPH than in nonsarcoid ILD-PH.
However, SAPH poses unique challenges in two respects.
Treatment trial phenotypes
The definition of optimal patient phenotypes for treatment trials must take into account the multiple
mechanisms driving SAPH. Ideally, based on research into haemodynamic profiles, individual phenotypes
will be integrated into combined phenotype trials or selectively excluded. Core phenotypes include
pre-capillary vasculopathy (whether due to direct granulomatous involvement or to pathways associated
with pulmonary fibrosis), vascular compression, and post-capillary pulmonary pathways (veno-occlusive
processes). When SAPH coexists with cardiac disease (including cardiac sarcoidosis and comorbidities),
robust algorithms will need to be developed to optimise inclusion and exclusion criteria. The distinction
between SAPH resulting from end-stage lung disease and other forms of SAPH needs to be considered
further, based on the definition of realistic treatment goals, short-term haemodynamic data in these patient
subgroups and accumulating data on the specific effects of individual candidate therapies. Imaging
assessment of the extent and distribution of parenchymal lung involvement in relation to the
haemodynamic profile will also be integral to any phenotyping.
Trial end-points
Because sarcoidosis is multidimensional in its nature, with variably severe co-existent pulmonary and
systemic disease, end-point selection is likely to be heavily influenced by the distinction between: 1)
short-term trials designed to establish safety and proof of concept; and 2) phase 3 studies evaluating major
clinical benefit. Pivotal end-point selection is not confined to the selection of the primary end-point but
includes the choice of key secondary end-points. There is a need to cover the spectrum of haemodynamic
effects, major clinical end-points (mortality, TCW), multidimensional functionality (6MWT data and
actigraphy) and measures of quality of life, crucially including patient-reported outcomes. In short-term
trials, haemodynamic effects may continue to be the primary focus but pivotal secondary end-points
should cover the domains listed above. In phase 3 trials, with clinical end-points likely to have primacy,
possible strategies include the use of co-primary end-points (e.g. TCW, 6MWT data) to capture both major
adverse outcomes and average cohort treatment effects. Composite end-points should be constituted by
relevant clinical outcomes including but not necessarily limited to cardiopulmonary hospitalisation,
mortality and categorical changes in 6MWT. In summary, whether the end-point focus is haemodynamic
or primarily clinical, depending upon trial duration, all domains should be represented by pivotal
secondary end-points, including the individual components of composite indices. Ongoing clinical
research, defining the optimal end-point and its performance characteristics, is pivotal. Continued efforts
are ongoing to identify biomarkers especially those that might identify longer-term efficacy based on
short-term change.

Optimal prognostic evaluation
Clinicians now have easy access to markers of PH, in SAPH and in ILD-PH alike. Noninvasive PH
markers in various forms of PH are listed in table 4. More clinical research is required in SAPH to validate
the prognostic significance of individual variables, with comparisons between variables of prognostic
values in large well-phenotyped cohorts. These should ideally include patients with SAPH and those with
less advanced disease, in order to identify earlier markers of pulmonary vasculopathy.
Composite noninvasive indices
Whether combinations of noninvasive indices, covering the multiple vasculopathic domains listed in the
previous section, may enhance prognostic evaluation is ripe for further investigation. Studies are ongoing
to determine optimal weighting of composite indices, defined by multivariable evaluation against key
https://doi.org/10.1183/16000617.0165-2021
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TABLE 4 Noninvasive PH markers
Cardiac functional impairment
Echocardiography
Cardiac magnetic resonance
PH severity evaluation
Echocardiography
Cardiac stress
BNP
Morphologic consequences
PA dilatation on CT
Global functional consequences
6MWD
Oxygen desaturation during 6MWD
Heart rate recovery
Pulmonary function vasculopathy profiles
Severe reduction in DLCO
DLCO reduction that is disproportionate to reductions in lung volumes – KCO, the DLCO/FVC ratio
PH: pulmonary hypertension; BNP: B-type natriuretic peptide; PA: pulmonary artery; CT: computed
tomography; 6MWD: 6-min walk distance; DLCO: diffusing capacity of the lung for carbon monoxide;
KCO: transfer coefficient of the lung for carbon monoxide; FVC: forced vital capacity.

clinical outcomes and by the presence of PH at RHC. In this way, the utility of noninvasive composite
indices in the selection of patients for RHC and their inclusion as end-points in pivotal trials can be
established.
Harnessing of technological advances
Recent advances in PH and in ILD have included deep phenotyping data (CT vascular morphometry,
SPECT/CT, PET metabolomics, four-dimensional MRI, machine learning) and in ILD, automated
quantification of pulmonary vascular volume using CALIPER, with major added value in prognostic
evaluation. In particular, it appears increasing likely that machine learning, applied both to individual
modalities and to combinations of techniques, will enhance prognostic evaluation. This is likely to be
particularly relevant to powering trials by selecting patients more likely to have adverse outcomes.
Summary and conclusion
SAPH is a significant cause of morbidity and mortality in advanced pulmonary disease. An approach to
detection of SAPH was developed by the committee. This approach relies on information from patient
history, physical examination, pulmonary function testing, chest imaging and serum biomarkers. The
echocardiogram remains the most commonly used next step in the patient with risk factors for SAPH.
However, RHC is needed to confirm the diagnosis and properly categorise the type of PH. Potential
treatments for SAPH are available. The committee felt that the interpretation of the RHC and the use of
specific treatments should be made by a multidisciplinary team including both a specialist in sarcoidosis
and PH.
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